Vibliome Therapeutics Expands Its Kinase Inhibitor Discovery Library

January 11, 2021 | Bozeman, MT

Vibliome Therapeutics, LLC, announced today that it has expanded its highly curated proprietary kinase inhibitor discovery library to more than 500 unique compounds. This library is built on a common chemotype the company is leveraging for the development of novel therapeutics targeting clinically relevant cell signaling pathways.

"This is an important milestone for the company," said Robert Goodwin, Vibliome's CEO. "We collect a large amount of data on each of our library compounds, including inhibition at multiple concentrations of more than 300 different wild-type kinases. The resulting data set gives us a unique ability to derive structure-activity relationships (SAR) for a large number of important kinase targets at the same time."

The analysis of Vibliome's discovery library has allowed the company to prioritize several projects for optimization to development candidate status for oncology indications. This further underscores the value in the company's approach to kinase inhibitor drug discovery. This includes the ability to identify tool compounds to unravel complex biologic questions, as well as differentiated lead candidates that will be investigated in future clinical trials. Kinase inhibitors are a cornerstone of oncology therapy and are a promising drug class to potentially treat a wide variety of immunologic and inflammatory diseases.

ABOUT VIBLIOME

Vibliome has discovered a new, systematic approach for the development of small molecule kinase inhibitors with unique profiles and a very high degree of selectivity. This platform technology is ideally suited to support emerging therapeutic approaches for cancer and other diseases where selective kinase targeting is needed. The company is based in Bozeman, Montana, and New York City. For more information or inquiries, please visit www.vibliome.com.

CONTACTS

Vibliome Therapeutics, LLC
Robert Goodwin, Ph.D.
406-595-3483
contact@vibliome.com